U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
ROCKVILLE, Md., Jan. 02, 2018 -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update for the Company, and host investor meetings at the 36th Annual J.P. Morgan Healthcare Conference.
Date: Wednesday, January 10, 2018
Time: 12:00 p.m. PT / 3:00 p.m. ET
Place: Westin St. Francis Hotel, San Francisco, CA
Investors interested in arranging a meeting with the Company's management during these conferences should contact the conference coordinator.
A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company's website at www.supernus.com. An archived replay of this webcast will be available for 60 days subsequent to the Company's presentation.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.
CONTACT:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Or
Investor Contact:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: [email protected]
